

May 11, 2021

Financial Summary
(For the fiscal year ended March 31, 2021)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: First Section of Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date of ordinary general meeting of shareholders: June 29, 2021

Scheduled date to commence dividend payments: June 30, 2021

Scheduled date to submit the Securities Report: June 29, 2021

Preparation of supplementary documents to the financial results: Yes

Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2020 through March 31, 2021)

(1) Consolidated Financial Results

(Percentage figures indicate changes from the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2021	55,442	(8.2)	3,442	(15.9)	3,175	(18.2)	3,119	6.6
March 31, 2020	60,426	(2.3)	4,094	9.6	3,879	17.7	2,925	(15.3)

Note: Comprehensive income: For the year ended March 31, 2021: 6,226 million yen [– %]

For the year ended March 31, 2020: (1,471) million yen [– %]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary profit to total assets	Operating profit to net sales
Year ended	Yen	Yen	%	%	%
March 31, 2021	67.72	—	5.7	2.8	6.2
March 31, 2020	62.62	—	5.2	3.6	6.8

Reference: Share of profit (loss) of entities accounted for using equity method: For the year ended March 31, 2021: – million yen

For the year ended March 31, 2020: – million yen

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2021	121,859	56,179	46.0	1,225.69
March 31, 2020	104,155	52,678	50.4	1,134.30

Reference: Equity: As of March 31, 2021: 56,012 million yen As of March 31, 2020: 52,510 million yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of term
Year ended	Million yen	Million yen	Million yen	Million yen
March 31, 2021	6,894	(17,460)	11,185	9,668
March 31, 2020	7,251	(405)	(5,877)	8,880

2. Dividends

	Annual dividends					Total dividends paid (Total)	Payout ratio (Consolidated)	Dividend rate for net assets (Consolidated)
	First quarter	Second quarter	Third quarter	Year-end	Total			
Year ended	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
March 31, 2020	—	17.00	—	17.00	34.00	1,576	54.3	2.9
March 31, 2021	—	17.00	—	17.00	34.00	1,561	50.2	2.9
Year ending March 31, 2022 (Forecast)	—	17.00	—	17.00	34.00		47.1	

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	29,000	—	2,100	—	2,200	—	1,500	—	32.82
Full year	60,000	—	4,800	—	4,800	—	3,300	—	72.21

Note: The “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29) and its related implementation guidance will be applied from the start of the fiscal year ending March 31, 2022. Accordingly, the figures presented above for consolidated forecasts reflect the application of the aforementioned accounting standard, etc. and year-on-year comparisons have been omitted.

* Notes

(1) Significant changes of subsidiaries during the fiscal year ended March 31, 2021 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: — (Company name: —) Exclusion: — (Company name: —)

(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(3) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of March 31, 2021: 53,119,190 shares As of March 31, 2020: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of March 31, 2021: 7,420,461 shares As of March 31, 2020: 6,825,944 shares

3) Average number of shares during the term:

For the year ended March 31, 2021: 46,071,761 shares

For the year ended March 31, 2020: 46,714,006 shares

Reference: Summary of Non-consolidated Financial Results

Non-consolidated Financial Highlights (April 1, 2020 through March 31, 2021)

(1) Non-consolidated Financial Results

(Percentage figures indicate changes from the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2021	33,999	(16.1)	356	(80.4)	1,055	(63.4)	1,250	(33.8)
March 31, 2020	40,545	(5.6)	1,816	17.4	2,880	9.2	1,889	(47.3)

	Basic earnings per share	Diluted earnings per share
Year ended	Yen	Yen
March 31, 2021	27.14	—
March 31, 2020	40.46	—

(2) Non-consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2021	95,014	41,356	43.5	904.99
March 31, 2020	83,055	42,234	50.9	912.32

Reference: Equity: As of March 31, 2021: 41,356 million yen As of March 31, 2020: 42,234 million yen

* Financial Summary Is Not Required to Be Audited by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.